Please use this identifier to cite or link to this item:
|Title:||Innovative Therapeutic and Delivery Approaches Using Nanotechnology to Correct Splicing Defects Underlying Disease|
|Author:||Suñé Pou, Marc|
Limeres, Maria J.
Moreno Castro, Cristina
Suñé i Negre, Josep M. (Josep Maria)
Cuestas, María L.
|Abstract:||Alternative splicing of pre-mRNA contributes strongly to the diversity of cell- and tissue-specific protein expression patterns. Global transcriptome analyses have suggested that >90% of human multiexon genes are alternatively spliced. Alterations in the splicing process cause missplicing events that lead to genetic diseases and pathologies, including various neurological disorders, cancers, and muscular dystrophies. In recent decades, research has helped to elucidate the mechanisms regulating alternative splicing and, in some cases, to reveal how dysregulation of these mechanisms leads to disease. The resulting knowledge has enabled the design of novel therapeutic strategies for correction of splicing-derived pathologies. In this review, we focus primarily on therapeutic approaches targeting splicing, and we highlight nanotechnology-based gene delivery applications that address the challenges and barriers facing nucleic acid-based therapeutics.|
|Note:||Reproducció del document publicat a: https://doi.org/10.3389/fgene.2020.00731|
|It is part of:||Frontiers In Genetics, 2020, vol. 11, num. 731, p. 1-22|
|Appears in Collections:||Articles publicats en revistes (Farmàcia, Tecnologia Farmacèutica i Fisicoquímica)|
This item is licensed under a Creative Commons License